BGI Genomics is a publicly listed commercial genomics company established in 1999. We provide a wide range of next generation sequencing services and bioinformatics services, and a broad portfolio of genetic tests to support medical institutions, research institutions, pharmaceutical companies and many other public and private partners.
Our business covers more than 100 countries and regions around the world, including more than 2,000 scientific research institutions and more than 2,300 medical institutions in China. We work with more than 3,000 institutions across Europe, North America and Asia Pacific.
Our expertise and scale allow us to provide quality data at extremely competitive pricing. Please visit our website to learn more about our solutions or get in touch directly via the form below.
DNBSEQ™ is a proprietary sequencing technology, first developed by BGI's Complete Genomics subsidiary in Silicon Valley, and can offer advantages in terms of lower amplification error rates and much lower duplication rates for some sequencing applications. In addition, studies have shown the index hopping rate in DNBSEQ™ platforms can be much lower when compared to that of other platforms.